Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1000 USD | -9.09% |
|
0.00% | -23.14% |
| Market Cap | 31.69M 22.49M 19.78M 18.37M 16.9M 2.18B 32.26M 220M 85.69M 1.06B 84.42M 82.59M 3.68B | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 31.46M 22.32M 19.63M 18.24M 16.77M 2.16B 32.02M 218M 85.07M 1.05B 83.8M 81.99M 3.66B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -9.09% | ||
| Current month | +5.26% | ||
| 3 months | +25.00% | ||
| Current year | -23.14% |
| 1 week | 0.1 | 0.11 | |
| 1 month | 0.09 | 0.11 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 2019-06-30 |
| Director of Finance/CFO | - | 2022-08-16 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 2024-09-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 2017-12-05 |
Brad Willis
BRD | Director/Board Member | - | 2019-06-30 |
Eric Pommer
CHM | Chairman | - | 2025-04-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -9.09% | 0.00% | - | - | 22.49M | ||
| +1.97% | +1.43% | +48.44% | +156.66% | 1,057B | ||
| +1.42% | +3.72% | +53.32% | +52.34% | 624B | ||
| +1.43% | +0.99% | +34.83% | +78.74% | 454B | ||
| +0.64% | +5.06% | +32.44% | +28.37% | 341B | ||
| -0.61% | +1.57% | +35.74% | +39.82% | 297B | ||
| -0.47% | +0.22% | +15.73% | +17.09% | 262B | ||
| -0.71% | -3.41% | -28.72% | -42.06% | 215B | ||
| +1.49% | -0.02% | +20.14% | +58.21% | 201B | ||
| +0.40% | -3.99% | +15.23% | +62.28% | 162B | ||
| Average | -0.35% | +0.77% | +25.24% | +50.16% | 401.55B | |
| Weighted average by Cap. | +1.04% | +1.57% | +34.99% | +75.48% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.36 |
| Net income | -1.71M -1.21M -1.07M -990K -910K -117M -1.74M -11.84M -4.62M -57.22M -4.55M -4.45M -199M | -3.53M -2.51M -2.2M -2.05M -1.88M -243M -3.6M -24.49M -9.55M -118M -9.41M -9.21M -411M |
| Net Debt | -113K -79.92K -70.29K -65.3K -60.06K -7.74M -115K -781K -305K -3.78M -300K -294K -13.1M | -231K -164K -144K -134K -123K -15.84M -235K -1.6M -623K -7.73M -614K -601K -26.81M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-22 | US$0.1000 | -9.09% | 47,000 |
| 26-07-21 | US$0.1100 | +10.00% | 39,000 |
| 26-07-20 | US$0.1000 | 0.00% | 14,000 |
| 26-07-17 | US$0.1000 | 0.00% | 6,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















